Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Scienture Holdings Inc (SCNX)

Scienture Holdings Inc (SCNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 20,116
  • Shares Outstanding, K 40,631
  • Annual Sales, $ 140 K
  • Annual Income, $ 9,070 K
  • EBIT $ -17 M
  • EBITDA $ -16 M
  • 60-Month Beta 2.95
  • Price/Sales 151.67
  • Price/Cash Flow N/A
  • Price/Book 0.21
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.00
  • Most Recent Earnings $-0.19 on 11/12/25
  • Next Earnings Date 03/24/26
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4900 +1.31%
on 12/30/25
0.7500 -33.81%
on 12/10/25
-0.1027 (-17.14%)
since 11/28/25
3-Month
0.4610 +7.68%
on 10/21/25
2.6000 -80.91%
on 10/23/25
-0.3531 (-41.57%)
since 09/30/25
52-Week
0.4610 +7.68%
on 10/21/25
6.4466 -92.30%
on 12/31/24
-5.7036 (-91.99%)
since 12/30/24

Most Recent Stories

More News
SCIENTURE Provides Update on the Commercial Launch of REZENOPY®, the Highest Strength Naloxone HCl Life-Saving Opioid Overdose Emergency Treatment Approved by the FDA

U.S. Naloxone Market: ~$154 million in annual sales and 9.3 million units annually COMMACK, NY, Dec. 22, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company...

SCNX : 0.4974 (+0.46%)
SCIENTURE and BlinkRx Announce Strategic Collaboration to Expand Patient Access to Arbliâ„¢, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium

U.S. Losartan market totals $245M annually with 71M prescriptions  COMMACK, NY, Dec. 10, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and...

SCNX : 0.4974 (+0.46%)
Updated Lineup Announced for iAccess Alpha's Virtual Best Ideas Winter Investment Conference December 9-10, 2025

RALEIGH, NC / ACCESS Newswire / December 8, 2025 / iAccess Alpha's Virtual Best Ideas Winter Investment Conference will take place on December 9-10, 2025, bringing together top micro-cap companies and...

MOB : 6.10 (+1.84%)
BOSC : 4.68 (-0.21%)
STRT : 77.94 (+1.02%)
ELWT : 4.74 (+2.38%)
FLUX : 1.2850 (-0.39%)
DGX.VN : 3.510 (-0.85%)
BCHT.TO : 1.07 (-2.73%)
GAME : 0.3897 (-2.58%)
WYY : 5.49 (-0.36%)
ACNT : 16.49 (-0.36%)
DCGO : 0.8861 (+0.66%)
VELO : 13.98 (-4.05%)
SCIENTURE to Participate in the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9–10, 2025

COMMACK, NY, Dec. 02, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced...

SCNX : 0.4974 (+0.46%)
iAccess Alpha's Virtual Best Ideas Winter Investment Conference December 9-10, 2025

RALEIGH, NC / ACCESS Newswire / December 1, 2025 / iAccess Alpha's Virtual Best Ideas Winter Investment Conference will take place on December 9-10, 2025, bringing together top micro-cap companies and...

MOB : 6.10 (+1.84%)
BOSC : 4.68 (-0.21%)
STRT : 77.94 (+1.02%)
ELWT : 4.74 (+2.38%)
DGX.VN : 3.510 (-0.85%)
BCHT.TO : 1.07 (-2.73%)
GAME : 0.3897 (-2.58%)
ACNT : 16.49 (-0.36%)
WYY : 5.49 (-0.36%)
DCGO : 0.8861 (+0.66%)
DGXX : 2.56 (-1.16%)
SCNX : 0.4974 (+0.46%)
SCIENTURE Reports Q3 2025 Financial Results and Provides Business Update

Reports Significant Revenue Growth to $590K and Substantial Increase in Gross Profit to $575K Launched Sales of Arbli â„¢ , the First FDA-Approved Ready-To-Use Liquid Formulation of Losartan for...

SCNX : 0.4974 (+0.46%)
Scienture Holdings: Q3 Earnings Snapshot

Scienture Holdings: Q3 Earnings Snapshot

SCNX : 0.4974 (+0.46%)
SCIENTURE Announces Addition of Arbliâ„¢ (Losartan Potassium) to Formularies of Major National Health Plans

Expanded Coverage Reaches Over 100 Million Covered Lives Nationwide COMMACK, NY, Nov. 04, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and...

SCNX : 0.4974 (+0.46%)
SCIENTURE Announces Start of Commercial Sales and Fulfillment of First Orders for Arbliâ„¢ (Losartan Potassium)

Company launches multi-channel promotional campaign to drive market adoption U.S. losartan market totals $256M annually with 71M prescriptions, creating a significant opportunity for Arbli â„¢...

SCNX : 0.4974 (+0.46%)
SCIENTURE’S Arbli™ Becomes First FDA-Approved Ready-to-Use Liquid Losartan Available Through Major U.S. Wholesalers

Novel oral suspension addresses critical patient safety needs for hypertension treatment for patients unable to swallow tablets U.S. losartan market totals $256M annually with 71M prescriptions, creating...

SCNX : 0.4974 (+0.46%)

Business Summary

Scienture Holdings Inc., through its wholly owned subsidiaries, Scienture and Integra Pharma Solutions, LLC, is a comprehensive pharmaceutical product company focused on providing enhanced value to patients, physicians and caregivers by offering novel specialty products to satisfy unmet market needs....

See More

Key Turning Points

3rd Resistance Point 0.5284
2nd Resistance Point 0.5197
1st Resistance Point 0.5074
Last Price 0.4974
1st Support Level 0.4864
2nd Support Level 0.4777
3rd Support Level 0.4654

See More

52-Week High 6.4466
Fibonacci 61.8% 4.1601
Fibonacci 50% 3.4538
Fibonacci 38.2% 2.7475
Last Price 0.4974
52-Week Low 0.4610

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar